FX1

Item no.	HY-102027-50mg
Manufacturer	MedChem Express
CASRN	1426138-42-2
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 25 mg 50 mg 5 mg
Category	Oncology Food Safety Allergenes Neuroscience Neural Lineage Markers Neuroinflammation Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Heart & Blood Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]Mariano G et al. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest. 2016 Sep 1; 126(9): 3351–3362.
Smiles	O=C(O)CCN(C/1=O)C(SC1=C2C(NC3=C/2C=C(Cl)C=C3)=O)=S
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1426138-42-2
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; Bcl-2 Family
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	368.82
Product Description	FX1 is a potent and specific BCL6 inhibitor, with an IC50 of around 35 μM.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 10 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-102027-50mg-safety-datasheet.pdf